Skip to main content

Post-IPO Secondary Therapeutics Companies

Explore 4 therapeutics startups that raised post-ipo secondary funding. Access verified founder contact information and fundraising data.

Total Companies
4
Total Funding
$566.2M
Avg Funding
$141.6M
Cities
3

Export 4 Post-IPO Secondary Therapeutics Companies

Get founder emails, funding data, and company details in one CSV

Start Free Trial

Recently Funded Companies

Export
Warsaw, Poland
$12.6M
raised

Molecure is an innovative biopharmaceutical company that specializes in discovery, development, and commercialization of novel therapeutics.

Jul 2023
Post-IPO Secondary

Founder Contacts

41,000+ verified contacts

Chellaston, United Kingdom
$3.6M
raised

Thalia Therapeutics is a drug reformulation company.

Jun 2026
Post-IPO Secondary

Founder Contacts

41,000+ verified contacts

Cambridge, United States
$50.0M
raised

Werewolf Therapeutics operates as an oncology biotherapeutics company.

May 2022
Post-IPO Secondary

Founder Contacts

41,000+ verified contacts

Cambridge, United States
$500.0M
raised

Nuvalent is a biopharmaceutical company that develops targeted therapies for cancer by designing small-molecule medicines.

Nov 2025
Post-IPO Secondary

Founder Contacts

41,000+ verified contacts

Ready to Connect with Post-IPO Secondary Therapeutics Startups?

Get verified founder emails, funding details, and company data for 4 post-ipo secondary therapeutics companies.

Get Started - Access Contact Information

Join thousands of sales teams, investors, and service providers using VCBacked